Venturini et al. BMC Infectious Diseases 2014, 14(Suppl 1):S5 http://www.biomedcentral.com/1471-2334/14/S1/S5
Frontiers in Public Health | www.frontiersin.org 1 June 2017 | Volume 5 | Article 127
Zhou et al. Int J Ment Health Syst (2019) 13:10 https://doi.org/10.1186/s13033-019-0263-1
Guideline
SAJHIVMED DECEMBER 2013, Vol. 14, No. 4
PLOS ONE | DOI:10.1371/journal.pone.0172392 February 16, 2017
PLOS ONE | https://doi.org/10.1371/journal.pone.0183180 October 9, 2017
Guide technique pour la prise en charge des maladies cardiovasculaires dans le cadre des soins de santé primaires
The U.S. President‘s Emergency Plan for AIDS Relief
Southern African Journal of HIV Medicine
ISSN: (Online) 2078-6751, (Print) 1608-9693
http://www.sajhivmed.org.za
Published: 23 May 2018
PLOS ONE | https://doi.org/10.1371/journal.pone.0196380 May 15, 2018
Global AIDS Update 2018
Closing Gaps
Breaking Barriers
Righting injustices
Combler les écarts
Rompre les barrières
Réparer les injustices
Synthèse
Global HIV Strategic Information Working Group
For Populations At Risk For HIV
This third booklet of the World Drug Report 2022 has a dual focus: opioids and cannabis.
The first chapter of the booklet provides an overview of opioids as a group of substances and their patterns of non-medical use at the global level. It also reviews the latest trends in the global supply of opi...ates and synthetic opioids and the availability of pharmaceutical opioids for medical consumption. Issues specific to regional patterns and trends in opioid markets are also analysed, including the opioid crisis in North America and in Africa and the Middle East. The chapter also includes a discussion of the potential impact, in the region and worldwide, of changes in opium poppy cultivation and opium production in Afghanistan. reireg
more
Gender-based Violence Area of Responsibility Working Group July 2010
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more